31 related articles for article (PubMed ID: 24152827)
1. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.
Li Z; Jiang X; Chen P; Wu X; Duan A; Qin Y
Oncol Lett; 2018 Sep; 16(3):4033-4042. PubMed ID: 30128025
[TBL] [Abstract][Full Text] [Related]
2. Combination of ultrasound and serological tests for detecting occult lateral lymph node metastases in medullary thyroid cancer.
Xiao J; Jiang J; Chen W; Hong T; Li B; He X; Liu W
Cancer Med; 2023 May; 12(10):11417-11426. PubMed ID: 37004158
[TBL] [Abstract][Full Text] [Related]
3. BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture.
Samimi H; Tavakoli R; Fallah P; Naderi Sohi A; Amini Shirkouhi M; Naderi M; Haghpanah V
Cancer Cell Int; 2022 Dec; 22(1):388. PubMed ID: 36482411
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Generalizability of the MultiFlow ® DNA Damage Assay and Several Companion Machine Learning Models With a Set of 103 Diverse Test Chemicals.
Bryce SM; Bernacki DT; Smith-Roe SL; Witt KL; Bemis JC; Dertinger SD
Toxicol Sci; 2018 Mar; 162(1):146-166. PubMed ID: 29106658
[TBL] [Abstract][Full Text] [Related]
5. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Falvo L; De Vito C; Catania A; Tartaglia F; Mocini R; Coccaro C; Alessandrini S; Barollo S; Mian C; Antonelli A; De Antoni E; D'Armiento M; Ulisse S
PLoS One; 2015; 10(3):e0121514. PubMed ID: 25807528
[TBL] [Abstract][Full Text] [Related]
6. A new aurora in anaplastic thyroid cancer therapy.
Baldini E; D'Armiento M; Ulisse S
Int J Endocrinol; 2014; 2014():816430. PubMed ID: 25097550
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinases: new molecular targets in thyroid cancer therapy.
Baldini E; Sorrenti S; D'Armiento E; Prinzi N; Guaitoli E; Favoriti P; Gnessi L; Moretti C; Bianchini M; Alessandrini S; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012 Nov; 163(6):e457-62. PubMed ID: 23306762
[TBL] [Abstract][Full Text] [Related]
8. Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Sarvagalla S; Coumar MS
Curr Cancer Drug Targets; 2015; 15(5):375-93. PubMed ID: 25895501
[TBL] [Abstract][Full Text] [Related]
9. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
10. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
[TBL] [Abstract][Full Text] [Related]
11. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
[TBL] [Abstract][Full Text] [Related]
13. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
14. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
